Back to School: How biopharma can reboot drug development. Access exclusive analysis here

LE-SN38: NEOL filed an IND with the FDA to begin by year end a Phase I/II trial of LE-SN38. The company plans to use LE-SN38 to treat other cancers in addition

NeoPharm Inc. (NEOL), Lake Forest, Ill.
Product: LE-SN38
Business: Cancer
Therapeutic

Read the full 116 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE